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SUMMARY
The secreted protein calcium-activated chloride chan-
nel regulator 1 (CLCA1) utilizes a vonWillebrand factor
type A (VWA) domain to bind to and potentiate the cal-
cium-activated chloride channel TMEM16A. To gain
insight into this unique potentiation mechanism, we
determined the 2.0-A˚ crystal structure of human
CLCA1 VWA bound to Ca2+. The structure reveals the
metal-ion-dependent adhesion site (MIDAS) in a
high-affinity ‘‘open’’ conformation, engaging in crystal
contacts that likely mimic how CLCA1 engages
TMEM16A. The CLCA1 VWA contains a disulfide
bond between a3 and a4 in close proximity to the
MIDAS that is invariant in the CLCA family and unique
inVWAstructures. Furtherbiophysical studies indicate
that CLCA1 VWA is preferably stabilized by Mg2+ over
Ca2+ and thata6atypically extends from theVWAcore.
Finally, an analysis of TMEM16A structures suggests
residues likely tomediate interactionwithCLCA1VWA.
INTRODUCTION
The calcium-activated chloride channel regulator 1 (CLCA1) is
emerging as an important channel-modifying protein with poorly
definedroles inhealthanddisease (Patel etal., 2009;Sala-Rabanal
et al., 2015a). CLCA1 is a secretedprotein that binds to andpoten-
tiates the calcium-activated chloride channel TMEM16A (Sala-Ra-
banal etal., 2015b). In theairwaysanddigestive tracts, anionchan-
nels play important roles in mediating mucus hydration and pH
balance for protective and digestive purposes. CLCA1 and other
CLCA family members have often been associated with airway
and digestive manifestations. For example, animal models and
clinical studies suggest a compensatory role for CLCAs in the
context of cystic fibrosis (CF). The fatal intestinal disease meco-
nium ileus that arises in cystic fibrosis transmembrane conduc-
tance regulator (CFTR)-deficient mice is corrected by overexpres-
sion of mouse CLCA1 (Young et al., 2007). Correspondingly,
variants of either CLCA1 (van der Doef et al., 2010) or CLCA4
(Kolbe et al., 2013) have been linked to more severe meconium
ileus in humans. In addition, the therapeutic peptide thymosin
alpha 1 (Ta1) has been observed to rectify multiple airway and in-
testinaldefects inamousemodel ofCF,whichmaybepartially due
to increasing CLCA1 expression and, thus, potentiation of
TMEM16A (Romani et al., 2017). By similar arguments, TMEM16A
has emerged as a therapeutic target for CF and other muco-
obstructivediseases (Li etal., 2017;Mall andGalietta, 2015;Sondo
et al., 2014). Inhibiting microRNA (miRNA)-mediated knockdown
of TMEM16A results in increased chloride flux and mucociliary
clearance in CF cell lines, primary CF cells, and mouse models
(Sonneville et al., 2017). Increased TMEM16A activity has also
been linked to other processes that are important to the resolution
of CF airway disease: cell migration and proliferation for wound
healing (Ruffin et al., 2013; Sonneville et al., 2017) and suppression
of inflammatory cytokine production (Veit et al., 2012). Based on
these and other observations, both CLCA1 and TMEM16A have
beensuggestedas targets for stimulation inmuco-obstructivedis-
eases—either to compensate or bypass dysfunctional CFTR inCF
or to stimulate secretion to solubilize obstructivemucus in asthma
and chronic obstructive pulmonary disease (COPD) (Mall et al.,
2018). Such efforts require a detailed molecular level understand-
ing of the mechanism of potentiation.
The ability of CLCA1 to potentiate TMEM16A is regulated by
a matrix-metalloprotease-like (MMP-L) domain found in the N ter-
minus of CLCA1. During secretion, CLCA1 MMP-L cleaves
CLCA1 into two fragments, allowing the N-terminal fragment of
CLCA1 (N-CLCA1) to engage TMEM16A (Yurtsever et al., 2012).
This engagement is mediated between the von Willebrand factor
type A (VWA) domain in CLCA1 and the a9-a10 loop in TMEM16A
and increases the surface expression of TMEM16A, thereby
increasing currents (Sala-Rabanal et al., 2015b, 2017). The
CLCA1 VWA domain (CLCA1 VWA) alone is necessary and suffi-
cient to potentiate TMEM16A (Sala-Rabanal et al., 2017). VWA do-
mainscommonlymediateprotein-protein interactions,withinwhich
the integrin aI subfamily has been the most well-characterized
structurally and biophysically (Luo et al., 2007). Most contain a
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metal-ion-dependent adhesion site (MIDAS) motif to mediate pro-
tein-protein interactions (Springer, 2006; Whittaker and Hynes,
2002). MIDAS motifs consist of a loop containing a DXSXS
sequence, a second loop containing a threonine (T4), and a third
loop containing an aspartate (D5) that acts to chelate and present
adivalent cation (usuallyMg2+) to ligandscontainingacidic residues
(Asp or Glu), which then complete the coordination sphere for the
divalent cation upon binding (Luo et al., 2007). Sequence analysis
indicates that these MIDAS residues are present in CLCA1 VWA
(Whittaker and Hynes, 2002), and we have shown that this motif
and the divalent cation are necessary for CLCA1 potentiation of
TMEM16A (Sala-Rabanal et al., 2017).
VWA domains are found in a functionally diverse range of
proteins, including blood coagulation factors (von Willebrand
factor), complement factors (Springer, 2006), signaling receptors
(a integrins; Shimaoka et al., 2002), toxin receptors (anthrax
toxin receptors; Lacy et al., 2004a, 2004b; Santelli et al., 2004),
extracellular matrix (collagen, Becker et al., 2014; and matrillin,
Paulsson and Wagener, 2018), ion channel regulators or sub-
units (CLCAs, Patel et al., 2009; and Cav1.1 a2d1, Dolphin,
2016), as well as in critical proteins in bacterial pathogens such
as Plasmodium (Song et al., 2012) and Toxoplasma (Song and
Springer, 2014). Structural and biophysical studies have been
carried out for several of these proteins, with those from a integ-
rins, von Willebrand factor, and complement factors being the
best characterized (Springer, 2006). All adopt a Rossman fold
composed of a b sheet surrounded by amphipathic a helices
(Rossmann et al., 1974). However, there are often structural
and functional features that are unique to distinct families of
VWA domains (Becker et al., 2014; Song et al., 2012; Song
and Springer, 2014; Springer, 2006). To date, no high-resolution
structure has been determined for a VWA domain from the
CLCA phylogenetic branch. All CLCA proteins, with the excep-
tion of the CLCA3 pseudogenes (Mundhenk et al., 2018), contain
a central VWA domain (Figure 1). To gain insight into the unique
structural features of CLCA VWA domains, as well as how
CLCA1 VWA might engage TMEM16A, we determined the
high-resolution crystal structure of CLCA1 VWA. The structural
information suggests the mode by which CLCA1 engages
TMEM16A and themost likely sites on TMEM16Awhere engage-
ment occurs.
RESULTS
Crystal Structure of the CLCA1 VWA
Human CLCA1 VWA (Figure 1A) was purified from a mamma-
lian cell expression system and was previously shown to be
functional in potentiating TMEM16A when exogenously applied
Figure 1. Structure of Human CLCA1 VWA Domain
(A) Domain architecture schematic of full-length human CLCA1. Labels denote the following domains: CAT, matrix-metalloprotease-like catalytic domain; Cys,
matrix-metalloprotease-like cysteine-rich region; FnIII, fibronectin type III domain; VWA, von Willebrand factor type A. Numbers above the domains indicate
approximate domain boundaries. Dashed line indicates cleavage site.
(B) Ribbon diagram of the human CLCA1 VWA domain structure obtained by X-ray crystallography. b strands and a and h helices of the VWA domain are labeled
according to the vWFA2 nomenclature (Zhang et al., 2009). A calcium ion (Ca2+) coordinated by the VWA MIDAS motif is shown as a gray sphere. MIDAS motif
residues surrounding the divalent cation are highlighted. The three invariant cysteines and location of the disease-associated variant S357 are also labeled. N, N
terminus; C, C terminus.
(C–F) Human CLCA1 VWA domain is superpositioned to anthrax toxin receptors CMG2 (PDB: 1SHU) (C) and TEM8 (PDB: 3N2N) (D), CD11b aI domain (PDB:
1IDO) (E), and collagen (PDB: 4IGI) (F) VWA domains. MIDASmotifs are indicated for all alignments. The h2 helix of the CLCA1 VWA domain and the a6 helices of
the published VWAdomain structures are labeled in (C)–(E). For all structures, the CLCA1 disulfide is annotated by solid lines. For (A), the natural disulfide in CMG2
is annotated by dashed lines. For (F), the N and C termini are labeled.
See also Figures S1 and S2.
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to HEK293 cells (Sala-Rabanal et al., 2017). The structure was
determined by molecular replacement at a 2.0-A˚ resolution
(Table 1). There are two molecules in the asymmetric unit
(ASU) that are highly similar (Ca root-mean-square deviation
[RMSD] of 0.3 A˚; Figure S1). Therefore, unless otherwise noted,
our analysis of CLCA1 VWA will refer to chain B. The general
structural features are similar to other VWA domain folds: a
core composed of 6 b strands sandwiched between a-helical
bundles (Figure 1B). A DALI structure comparison revealed that
the CLCA1 VWA shares the most three-dimensional similarity
to anthrax toxin receptors CMG2 (Lacy et al., 2004b) and
TEM8 (Fu et al., 2010) and to the voltage-dependent L-type
calcium channel Cav1.1 subunit a2d (Wu et al., 2015, 2016; Fig-
ures 1C–1E) with RMSDs ranging from 1.9–2.3 A˚ (Holm and
Laakso, 2016). However, there are three notable exceptions in
comparison to these VWA domains from other families. First,
the b sheet core is usually encompassed by 6 a helices. Although
the last a helix, a6 (using the nomenclature of the VWA2 domain;
Zhang et al., 2009), is predicted by secondary structure predic-
tions (JPRED4; Drozdetskiy et al., 2015; see Figure 3A) and is
present in this construct (residues 302–476), we did not observe
defined electron density for it. Also, a slightly longer construct
(residues 302–478) did not yield a map with a6 clearly present
(Figure S2; Table S2). The absence of a6 places the N and C
termini of the CLCA1 VWA on opposite ends, much like the
arrangement reported in the structure of a collagen VI VWA
domain (Figure 1F; Becker et al., 2014). If in solution a6 is not
packed against the domain (see Discussion), this could have im-
plications for how the domains of CLCA1 are oriented relative to
one another or may facilitate cleavage of the N-CLCA1 from C-
CLCA1. Second, there is a disulfide bond in proximity of the
MIDAS residues, linking a3 and h2 of a4 (Figure 1B). The cyste-
ines in this disulfide linkage are unique to the CLCA family of
VWA domains. Most VWA domains do not contain a disulfide
bond, and if one is present, it usually connects the N- and C-ter-
minal boundaries of the domain (Figure 1C). Third, there is a 310
helix (h2) at the N terminus of a4 that ends with one of the disul-
fide-bonded cysteines (Figures 1B–1E). Beyond the secondary
structure, CLCA1 VWA differs most in the loops surrounding
the MIDAS, as would be expected, because these loops usually
dictate ligand-binding specificities of VWA domains (Luo et al.,
2007).
CLCA1 VWA Crystallizes with MIDAS in the Open
Conformation
Most VWA domains mediate protein-protein interactions by a
MIDAS motif, which partially coordinates a divalent cation in a
manner that encourages completion of the coordination sphere
by an acidic residue (Asp or Glu) contributed by the ligand
(McCleverty and Liddington, 2003; Nolte et al., 1999; Shimaoka
et al., 2003; Springer, 2006; Vorup-Jensen et al., 2003). MIDAS
motifs have been observed to exist in two conformations that
correspond to the affinity of the VWA domain for its ligand: an
open, high-affinity configuration and a closed, low-affinity
configuration (Shimaoka et al., 2003). The closed conformation
is defined by MIDAS D5 serving as a direct chelator of the
divalent cation, through which the motif partially satisfies its
electrophilic nature (Figure 2D). In contrast, the open configura-
tion is hallmarked by all the direct MIDAS chelators of the diva-
lent cation being uncharged (threonine, serine, or waters),
creating an electrophilic divalent cation whose coordination is
best satisfied by an acidic residue contributed by the engaging
ligand (Figure 2C). The human CLCA1 VWA contains a perfectly
conserved MIDAS motif (Whittaker and Hynes, 2002): a DXSXS
sequence followed several residues later by a threonine (T383)
and a final aspartate (D412) (Figure 2A). Strong density corre-
sponding to an ion was observed at the center of this site for
both molecules in the ASU (Figure S3). As the CLCA1 VWA
was crystallized in conditions containing high CaCl2 concentra-
tions, we modeled a Ca2+ into the MIDAS site. Very few VWA
domains have been crystallized in the presence of Ca2+ and
instead usually containMg2+ orMn2+ that bind at a higher affinity.
Most VWA MIDAS motifs favor occupancy by Mg2+ rather than
Table 1. Crystallographic Statistics for Human CLCA1 VWA
Parameter Data
Construct 302–476
Data collection statistics
Space group C2
Unit cell
a, b, c (A˚) 104.9, 71.8, 74.8
a, b, g () 90, 109.8, 90
Source ALS 4.2.2
Wavelength (A˚) 1.0000
Resolution (A˚) 58.05–2.00 (2.05–2.00)
Rmerge 0.090 (1.814)
CC1/2 0.998 (0.507)
Completeness (%) 98.3 (86.3)
Redundancy 6.4 (4.2)
I/s (I) 10.7(0.6)
Refinement statistics
Rwork (%) 19.87
Rfree (%) 22.51
Amino acid residues (#) 318
Waters (#) 148
RMSD bond length (A˚)/angles () 0.011/1.181
Wilson B (A˚2) 36.7
Average B protein (A˚2) 44.57
Average B water (A˚2) 47.51
Average B Ca2+ (A˚2) 37.50
Ramachandran
% Favored 96.82
% Allowed 3.18
% Outliers 0
Rotamer outliers (%) 3.53
Clashscore 3.41
Molprobity 1.74
Luzzati error 0.284
PDB ID 6PYO
Values shown in parantheses () represent the highest resolution shell. See
also Table S2.
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Ca2+, and Mg2+ coordination usually results in higher-affinity
binding to ligand or greater functional capability (Ajroud et al.,
2004; Baldwin et al., 1998; San Sebastian et al., 2006; Vorup-
Jensen et al., 2007). However, attempts to obtain CLCA1 VWA
crystals in the presence of excess MgCl2 were not successful.
For both molecules in the ASU, the structure reveals the
MIDAS in the open, high-affinity conformation, with S314,
S316, and T383 directly coordinating a calcium ion and D312
and D412 indirectly coordinating through a water molecule (Fig-
ures 2A and 2B). This coordinating geometry is consistent with
our functional studies that showed (1) mutation of MIDAS resi-
dues, particularly T383 and S316, which both directly coordinate
the divalent cation in the open conformation; and (2) chelation of
extracellular Mg2+ by EDTA abrogated CLCA1 VWA-mediated
potentiation of TMEM16A in whole-cell patch clamp experi-
ments (Sala-Rabanal et al., 2017). An acidic residue from an
adjacent molecule in the crystal, either a glutamate from chain
A (E299) or aspartate (D403) from chain B, completes the coor-
dination of the calcium ion. This arrangement is identical to the
open conformation observed for the CD11b aI domain (Fig-
ure 2C) with the exception that, unlike the CD11b structure
reported by Mahalingam et al. (Mahalingam et al., 2011), the
acidic residue appears to mediate a monodentate interaction
with calcium rather than a bidentate interaction. Such crystal
contact ‘‘pseudoligand’’ interactions are commonly observed
in crystal structures of VWA domains that utilize their MIDAS
motif to mediate interactions (Bhattacharya et al., 2004; Lacy
et al., 2004b; Lee et al., 1995; Li et al., 1998). The presence of
Figure 2. CLCA1 VWAMIDASCrystallizes in
an Open Conformation
(A–D) MIDAS regions of human CLCA1 chain B (A,
in green) and chain A (B, in cyan) of the asymmetric
unit and of the open (C) and closed (D) MIDAS
configurations of the CD11b aI domain (PDB: 1IDO
and 1JLM, respectively).
For (A)–(C), the pseudoligand residue is shown in
the color of the appropriate chain. Waters are
depicted as red spheres. Bonds coordinating
divalent cations are shown as blue dashes (for
direct side chain interactions) and yellow dashes
(for indirect or water-mediated interactions).
See also Figure S3.
the open conformation in our structures
implies that the CLCA1 VWA likely adopts
this configuration for a high-affinity inter-
action with TMEM16A and also suggests
that the binding is primarily mediated by a
critical acidic residue within TMEM16A.
An Invariant Disulfide Bond Is
Required for Folding and Secretion
of CLCA1 VWA
Our high-resolution crystal structure of
CLCA1 VWA revealed a disulfide bond be-
tween C386 and C421, connecting a3 and
the h2 segment of a4 (Figure 1B). This di-
sulfide bond is unique in that (1) natural di-
sulfide bonds in VWA domains are not common; and (2) unlike
CMG2 (Lacy et al., 2004b), MIC2 (Song et al., 2012) and TRAP
(Song and Springer, 2014), VWA domains in which a disulfide
bond is found linking the N- and C-termini, the disulfide bridge
in the CLCA1 VWA is found in close proximity to the MIDAS. Inter-
estingly, sequence analysis indicates that CLCA proteins have
three invariant cysteines within the VWA domain (Figure 3A;
Patel et al., 2009). The free cysteine C308 is packed within the
core of CLCA1 VWA (0% sidechain solvent accessibility as calcu-
lated byNACCESS;Hubbard and Thornton, 1993; Figure 1B). This
likely negates the possibility that CLCA1VWAmay covalently bind
to itself or to other proteins, as is the case for someVWAdomains,
such as the Cav-1 and 2 calcium channel a2 subunits, which
remain covalently linked to the d subunit by a disulfide bond (Wu
et al., 2015, 2016) after proteolytic cleavage. To investigate the
structural importance of invariant cysteines in the CLCA1 VWA,
we carried out mutations to serine (C308S, C386S, C421S, and
C386S/C421S) and expressed them in HEK293T cells. Although
all proteins were expressed, only the C308Smutant was secreted
(Figure 3B), indicating that mutants with disrupted disulfide bond
formation were misfolded and retained in the secretory pathway.
Further supporting this observation, for the mutants that were not
secreted, a band at approximately twice the monomer size of
CLCA1 VWA (2 X 20kDa) was observed in cell lysates, suggesting
that aberrant disulfide bonds between molecules may have been
formed during misfolding and not sufficiently reduced in SDS-
PAGE (Figure 3B). To assess the role of this disulfide in CLCA1
VWA stability, we carried out circular dichroism (CD) and
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Figure 3. Biophysical Analysis of CLCA Family VWA Domain Invariant Cysteines
(A) Annotated sequence alignment for human, mouse, and pig CLCA VWA domains. Numbering corresponds to the sequence of human CLCA1. Secondary
structure of human CLCA1 is labeled above. A solid line indicates the disulfide bond observed in the crystal structure. Stars next to the sequence indicate that the
VWA domain contains an imperfect MIDAS (Whittaker and Hynes, 2002). Sequences are shown for hCLCA1 (GenBank: NM_001285.3), pCLCA1 (NM_214148.1),
mCLCA1 (NM_017474.2), hCLCA4 (NM_012128.3), pCLCA4a (XM_001926978.5), pCLCA4b (XM_003125934.5), mCLCA4a (NM_207208), mCLCA4b
(NM_001033199), hCLCA2 (NM_006536.6), pCLCA2 (XM_003125930.4), mCLCA2 (NM_178697.5), mCLCA3b (NM_139148), mCLCA3a1 (NM_009899), and
mCLCA3a2 (NM_030601) (where h, human; p, pig; m,mouse). Sequence conservation is color coded as follows: invariant residues (with the exception of cysteine
and invariant MIDAS residues), magenta; invariant cysteines, green; residues with a global similarity score of 0.75 or higher as determined by ESPript 3.0 software
(Robert and Gouet, 2014a), yellow; perfect MIDAS residues, blue; and imperfect MIDAS residues, cyan. Black boxes indicate the most strongly predicted sites of
N-linked glycosylation by NetNGlyc 1.0 software (Blom et al., 2004). The predicted a6 helix (JPRED4; Drozdetskiy et al., 2015) of the CLCA1 VWA domain is
labeled above the alignment in red. MIDAS residues are highlighted in purple. Invariant cysteines are labeled in yellow.
(B) Wild-type (WT) CLCA1 VWA domain and cysteine-to-serine mutants of the invariant disulfides (single mutants C308S, C386S, and C421S, and double mutant
C386S/C421S) were expressed in 293T cells. Supernatants and lysates were analyzed by western blot (anti-6-His). Pos. control, 6-histidine taggedMAM domain
from receptor tyrosine phosphatase m (SDS-PAGE molecular weight [MW] = 30 kDa).
(C) Circular dichroism spectra of the human CLCA1 VWA domain in the presence of EDTA (blue), magnesium (green), and calcium (orange), with (dashed line) or
without (solid line) reducing agent (DTT). Spectra are plotted as mean ellipticity per residue ± SD of triplicate recordings. Representative spectra of three in-
dependent experiments.
(D) Thermal denaturation of human CLCA1 VWA domain by determination of melting temperatures (TM) by monitoring circular dichroism at 222 nm (top panel) or
differential scanning fluorimetry (bottom panel) in the presence of EDTA (blue), magnesium (green), and calcium (orange), with (squares) and without (diamonds)
reducing agent (DTT). Representative TMs of three independent experiments. For circular dichroism, data are represented as the calculated TM and estimated
error from the ProScan software. For differential scanning fluorimetry, data are represented as mean ± SEM of triplicate samples.
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differential scanning fluorimetry (DSF) experiments. CD spectra of
CLCA1 VWA in the absence of divalent cations (+EDTA) varied
greatly with the addition of DTT, especially at wavelengths of
<215 nm, indicating partial unfolding upon reduction of the
disulfide bond (Figure 3C). In addition, thermal denaturation
studies by CD and DSF in the presence or absence of DTT
showed that reduction of the disulfidebonddecreased themelting
temperature (TM) by 2.6
C and 6.5C, respectively (Figure 3D).
Altogether, these results suggest that CLCA family VWA domains
contain an invariant disulfide that is required for folding and stabil-
ity. The role of the invariant free cysteine (C308) is unclear at this
time. However, it should be noted that the sidechain sulfhydryl
does hydrogen bond to the backbone carbonyl of L309, so this
sidechain likely contributes to the stability of the fold.
CLCA1 VWA Is Stabilized by 1 mM Mg2+ but Not Ca2+
Our crystallization studies seemed to indicate that CLCA1 VWA
might not preferentially bind Mg2+, as we were unable to obtain
crystals in the presence of Mg2+. This would be unusual because
VWA domains normally bind Mg2+ with affinities in the low micro-
molar range, with affinities for Ca2+ about 100-fold worse, in the
range of hundreds of micromolar (Ajroud et al., 2004; Baldwin
et al., 1998; San Sebastian et al., 2006; Vorup-Jensen et al.,
2007). To relatively rank the binding affinities of CLCA1 VWA for
the divalent cations,we assessedwhether Ca2+ orMg2+ impacted
thermal stability by usingCDandDSF thermal denaturation exper-
iments. Both analyses were consistent: Mg2+ significantly stabi-
lizes the VWA domain over Ca2+ or cation-free conditions
(+EDTA), increasing the TM of CLCA1 VWA by 1.0
C–1.2C by
CD and 8.6C–9.8C by DSF (Figure 3D). In addition, Mg2+ even
stabilized CLCA1 VWA under reducing conditions (DTM = +2.1
C
or +6.9C, by CD and DSF, respectively). In contrast, the addition
of 1mMCa2+was unable to shift the TM ofCLCA1VWAcompared
to cation-free conditions. These results are consistent with previ-
ous investigations of VWA domain affinities for divalent cations
(Ajroud et al., 2004; Baldwin et al., 1998; San Sebastian et al.,
2006; Vorup-Jensen et al., 2007) and indicate that CLCA1 VWA
preferentially binds Mg2+ over Ca2+.
Solution Structures of CLCA1 Suggest VWA a6 Extends
from the Core Fold
Because we were unable to observe definitive electron density
for the CLCA1 VWA a6 in our high-resolution crystal structure,
we utilized small-angle X-ray scattering (SAXS) to develop a
low-resolution envelope structure of the VWA domain (Figures
4A–4D) as well as CLCA1 containing the catalytic and VWA
domains with an inactivating mutation in the MMP-L domain
(CAT-CYS-VWA E157Q) (Figures 4E–4H). The CLCA1 VWA
structure was docked into these envelopes using SITUS.
Both envelopes display globular regions consistent with one-
domain (VWA; Figure 4D) or three-domain (CAT-CYS-VWA
E157Q; Figure 4H) proteins. However, both also included a
Figure 4. Solution Structures of CLCA1 VWA and CAT-CYS-VWA Proteins from SAXS Analysis
Solution SAXS for human CLCA1 VWA (302–476) (A–D) and CLCA1 E157Q (22–477) encompassing theMMP-L catalytic domain (CAT), cysteine-rich region (Cys),
and VWA (E–H).
(A and E) Raw SAXS data.
(B and F) Top panel, Guinier regions with SAXS data points (open circles) and fits (solid red line). Radius of gyration (Rg) is labeled above the line of fit. Bottom
panel, residual data points (open circles) of Guinier region with fits (solid red line).
(C and G) Distance distribution functions. Dmax is indicated next to the distribution.
(D and H) Ab initio SAXS envelope models. Models are the average of 10 independent DAMMIN predictions averaged in DAMAVER. CLCA1 VWA domain was
docked into the envelope using SITUS. Domain architecture schematics and cartoons are labeled above the SAXS envelopes. in (D) and (H). N and C termini are
labeled.
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tubular tail extending from the sphere in both envelopes. In light
of the missing a6 helix in our crystal structure, we speculate that
this tail may represent the a6 helix that cannot be resolved in the
crystal structure because it does not pack tightly against the rest
of the domain. Analysis of packing in the CLCA1 VWA crystal
shows that the C terminus for the built structure is located
adjacent to large solvent channels that would allow for multiple
positions for an a6 helix that extends from the core VWA.
Thus, solution structural studies by SAXS suggest that CLCA1
VWA a6 extends from the VWA core fold, in contrast to other
structurally characterized VWA domains.
Structural Insights into the Disease-Associated CLCA1
Variant S357N
In genomic analyses, S357N has been identified as a mutation
modifying the severity of intestinal disease occurring in CF pa-
tients, as it was associated with aggravated meconium ileus
(van der Doef et al., 2010). To gain mechanistic insight into how
this mutation might manifest in disease, we analyzed the struc-
tural environment of S357 in our CLCA1 VWA structure. S357 is
found distal to the MIDAS motif, and the sidechain hydroxyl do-
nates a hydrogen bond to the backbone carbonyl of the adjacent
residue (E358) (Figure 5). This results in the S357 sidechain being
mostly buried (4.8% side chain solvent accessibility by NAC-
CESS). Given the tightly packed environment, it is highly unlikely
that an asparagine at this position would be able to engage in the
same hydrogen bond, which might disrupt folding or folding ki-
netics and could result in reduced expression levels. This would
result in decreased potentiation of calcium-activated chloride
currents, reducing hydration and resulting in thick mucus plug-
ging of the intestine. This would be consistent with our published
functional studies in overexpression systems in which S357N
does not affect the ability of CLCA1 VWA to potentiate chloride
currents by TMEM16A (Sala-Rabanal et al., 2017). This is also
consistent with studies in CFTR knockout mice that show that
mouse CLCA1 expression is decreased in mice with aggravated
meconium ileus, which is rescued by overexpression of mouse
CLCA1 (Young et al., 2007).
Structural Implications for CLCA1 VWA Engagement of
TMEM16A
Our crystal structure of CLCA1 VWA reveals the MIDAS in the
high-affinity open configuration and engaging in pseudoligand
Figure 5. Disease-Associated Residue
S357 Sidechain Engages in an Intramolecu-
lar Hydrogen Bond
The sidechain of S357 and the backbone and
sidechain of E358 are highlighted. The sidechain
hydroxyl of S357 forms a hydrogen bond to the
backbone carbonyl of E358 (indicated by the
dashed yellow line).
interactions with crystal lattice neighbors.
These interactions mimic the mode by
which CLCA1 VWA would engage
TMEM16A. In our previous studies, we
showed that an antibody targeting the
TMEM16A a9-a10 loop could block binding of CLCA1 (Sala-Ra-
banal et al., 2015b). This result, in combination with our current
structural observations, suggests that an acidic residue located
in the TMEM16A a9-a10 loop is primarily responsible for medi-
ating interaction with the CLCA1 VWA MIDAS. To identify the
most likely candidate residues, we analyzed the recently deter-
mined cryoelectron microscopy (cryo-EM) structures of mouse
TMEM16A (Dang et al., 2017; Paulino et al., 2017), making
note of which acidic residues in this loop were most solvent
exposed. This loop contains 9 acidic residues, 5 of which are
highly solvent exposed (>60% sidechain solvent-accessible
surface in NACCESS) (Figure 6). These residues are all
conserved in human TMEM16A (corresponding to D851, D854,
E858, E869, and E874). Thus, one of these five residues is
most likely responsible for mediating the interaction with
CLCA1. Similar modes of engagement have been observed in
the voltage-gated calcium channels system, such as Cav1.1,
where cryo-EM structures reveal an interaction with the a2d
subunit VWA that appear to be primarily mediated by a single
acidic residue in the channel domain (Wu et al., 2015, 2016).
However, it is worth noting that more complex models, such as
three-way modes of engagement, have also been suggested in
this system (Briot et al., 2018). Future mutational, functional,
and structural studies will be required to identify which residues
in TMEM16A are responsible.
DISCUSSION
Here, we present the structural and biophysical analysis of
the CLCA1 VWA, the first structural characterization of a VWA
domain from the CLCA family of channel-modifying proteins.
Our analysis reveals major observations with respect to CLCA
function and a potential role in disease. First, our structure
reveals the MIDAS motif in the high-affinity open conformation,
engaging in pseudoligand contacts thatmimic themode bywhich
it would engage TMEM16A and suggesting that one of five acidic
residues in the a9-a10 loop are primarily responsible for medi-
ating the interaction (Figure 6). However, it should be noted that
the other two extracelluar loops in TMEM16A (a1-a2 loop and
a5-a6 loop) in the cryo-EM structure are in close proximity to
the a9-a10 loop (Paulino et al., 2017), and therefore, antibody
binding to the a9-a10 loop could potentially sterically hinder ac-
cess to these loops as well. So, potential involvement of these
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loops in engagement should not be ruled out. Analysis of
sequence alignments across species indicate that most CLCA4
proteins contain an intact MIDAS motif, whereas most CLCA2
family members do not, missing one or two key residues (Fig-
ure 3A). Because members of the CLCA2 family have been
observed to potentiate calcium-dependent chloride currents
(Gruber et al., 1999), this would indicate that either neighboring
residues compensate to complete a non-standard MIDAS motif
or CLCA2 proteins carry out this function utilizing a different
mode of engagement. Our crystal and solution structures suggest
that a6 of the CLCA1 VWA extends from the core, which may
potentially contribute to theCLCA1VWAMIDAS being accessible
to engage TMEM16A by directing trailing domains further away
from the VWA core structure.
CLCA VWA domains contain three cysteines that are invariant
across species (Figure 3A). Two of them (corresponding to
C386andC421 inCLCA1)engage inadisulfidebond that is unique
compared to other structurally characterized VWA domains. This
linkage appears to be required for folding and stability of the
domain. In addition, this disulfide is in close proximity to key resi-
dues of the MIDAS motif. This disulfide bond appears to bend
the h2 helix toward the MIDAS and possibly constrain both
the a2-a3 and the b4- h2 loops, which contain the conserved
MIDAS threonine (T383) and aspartic acid (D412), respectively,
potentially favoring the open configuration (Figures 2A–2C). It is
interesting to note that in the shift from an open to a closedMIDAS
configuration, it is these two MIDAS residues that alter their
coordination to the divalent cation (i.e., in the open configuration,
threonine directly coordinates the cation and the second aspartic
acid indirectly coordinates through water, but in a closed configu-
ration, threonine indirectly coordinates by water and the second
aspartic acid directly coordinates the cation) (Figures 2C and 2D;
Shimaoka et al., 2003). This disulfide, however, does not appear
Figure 6. Most Probable Sites of CLCA1-
TMEM16A Interaction Suggested by Struc-
tural and Functional Studies
The cryo-EM model of mouse TMEM16A
(mTMEM16A) dimer (PDB: 5OYB; Paulino et al.,
2017) (purple) with the a9-a10 loop (blue) and
labeled acidic residues in this loop shown in either
yellow (<60% solvent-accessible surface for
sidechain) or cyan (>60% solvent-accessible sur-
face for sidechain). CLCA1 VWA (green) is poised
on the extracellular face of mTMEM16A, as our
structural data suggest that interaction with
CLCA1 VWA MIDAS is likely mediated by one of
these residues. Divalent cations (Ca2+) are shown
in gray.
to shift the MIDAS preference for bind-
ing divalent cations. Previous computa-
tional and biophysical studies on aI
domains indicate that Mg2+ is preferred
to Ca2+ by 100- to 1,000-fold affinity
(Ajroud et al., 2004; Baldwin et al., 1998;
San Sebastian et al., 2006; Vorup-Jensen
et al., 2007). Our thermal denaturation
studies suggest similar trends for the
CLCA1 VWA, indicating that at near physiological concentrations
(1 mM), Mg2+ is preferred over Ca2+ and is likely the cation that
mediates the CLCA1-TMEM16A interaction in vivo. The third
invariant cysteine (C308 in CLCA1) is not required for folding or
stability. Interestingly, the Toxoplasma gondiimotility and invasion
protein MIC2 also has a cysteine in this position of b1 that, in
contrast, engages in a disulfide linkage with a4 (C164) in its VWA
domain (Song and Springer, 2014). This is not the case in CLCA
VWAs, as the structurally corresponding position (A392 located
in a3 of CLCA1) is either an alanine or glycine (Figure 3A). It is un-
clear at this time what its functional role is and why it is invariant
at this position.
The S357N variant of CLCA1 has been associated with
increased severity of meconium ileus in CF patients (van der
Doef et al., 2010). This residue is tightly packed and engages
in a stabilizing hydrogen bond with the backbone. It is unlikely
that a mutation to asparagine would be well accommodated
at this position. Thus, this mutation likely impacts the expression
level of CLCA1, thereby decreasing the ability to potentiate
TMEM16A. Clinical and animal model studies further support
the concept that reduced CLCA1 and TMEM16A activity
contributes to pathology in the CF airway and intestinal diseases.
For example, miRNA targeting TMEM16A is overexpressed in
CF airways, and inhibiting this miRNA-mediated knockdown of
TMEM16A results in increased chloride flux and mucociliary
clearance by TMEM16A in CF cell lines, primary CF cells, and
mouse models (Sonneville et al., 2017). In addition, the peptide
drug thymosin alpha 1 (Ta1) has been demonstrated to increase
anion conductance in F508del-CFTR airway cell lines and
mice, and depleting CLCA1 with small interfering RNA (siRNA)
greatly reduces the ion channel activity enhanced by Ta1 (Bene-
detto et al., 2017). Furthermore, CFTR-deficient mice with
increased meconium ileus display lower CLCA1 expression
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that is corrected by the overexpression of CLCA1 (Young et al.,
2007). Altogether, these published observations and our
previous results suggest that CLCA1-mediated enhancement
of TMEM16A activity plays an important role in mucosal
inflammatory diseases and, thereby, represents a viable thera-
peutic target. Our structural results and analysis provide an
important framework for studying the role of CLCA proteins in
health and disease.
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KEY RESOURCES TABLE
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Tom J.
Brett (tbrett@wustl.edu). All unique/stable reagents generated in this study are available from the Lead Contact without restriction.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
Expi293F cells (RRID: CVCL_D615; sex = female) used for high-level protein expression were cultured at 37C and 8%CO2 in serum-
free Expi293 Expression Media (ThermoFisher Scientific) supplemented with 0.5% penicillin/streptomycin (Pen/Strep, GIBCO). Hu-
man embryonic kidney 293T cells (ATCC Cat # CRL-3216, RRID: CVCL_0063; sex = female) were cultured at 37C and 5% CO2 in
Dulbecco’s modified Eagle’s medium (GIBCO) supplemented with 10% Fetal Bovine Serum (FBS), 1% Non-essential Amino Acids
(Corning Inc., Corning, NY), 1% Glutamax (GIBCO) and 1% penicillin/streptomycin (Pen/Strep, GIBCO).
METHOD DETAILS
Expression constructs
Human CLCA1 VWA domain constructs (302-476 and 302-478) and CAT-CYS-VWA (22-477) were cloned into the mammalian cell
expression vector pHLsec, which contains an optimized signal sequence and C-terminal 6-histidine tag for purification (Aricescu
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
HRP Conjugated Anti-6-histidine Bethyl Laboratories Cat# A190-114P; RRID: AB_162722
Deposited Data
Raw and Analyzed Data CLCA1 VWA 302-476 This paper PDB: 6PYO
Raw and Analyzed Data CLCA1 VWA 302-478 This paper PDB: 6PYX
CLCA1 VWA 302-476 Coordinates This paper PDB: 6PYO
CLCA1 VWA 302-478 Coordinates This paper PDB: 6PYX
CLCA1 VWA 302-476 SAXS This paper SASBDB: SASDH24
CLCA1 CAT-CYS-VWA 22-477 SAXS This paper SASBDB: SASHD34
Experimental Models: Cell Lines
Expi293F ThermoFisher Cat# A14527; RRID: CVCL_D615
HEK293T ATCC Cat# CRL-3216; RRID: CVCL_0063
Oligonucleotides
Primers for CLCA1 constructs and mutants,
see Table S1
This paper N/A
Recombinant DNA
pHLsec (Aricescu et al., 2006) N/A
pcDNA 3.1 ThermoFisher Cat# V79020
Software and Algorithms
Chirascan Software Applied Photophysics https://www.photophysics.com/systems/
chirascan-systems/chirascan/system-information/
Protein Thermal Shift Software ThermoFisher Cat#4466038
PHENIX (Adams et al., 2010) http://www.phenix-online.org/
COOT (Emsley et al., 2010) https://www2.mrc-lmb.cam.ac.uk/personal/
pemsley/coot/
PyMOL Schrodinger, LLC https://www.schrodinger.com/
XDS (Kabsch, 2010) http://xds.mpimf-heidelberg.mpg.de/
ATSAS (Franke et al., 2017) https://www.embl-hamburg.de/biosaxs/
software.html
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et al., 2006). Mutants (C308S, C386S, C421S and C386S/C421S) were first generated in full-length CLCA1 in the vector pcDNA 3.1
using QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent, Santa Clara, CA) (primer sequences in Table S1) and then
subcloned into pHLsec. All constructs were verified by sequencing.
Protein expression and purification
WT human CLCA1 VWA domains (302-476 and 302-478) and CAT-CYS-VWA (22-477) were expressed in Expi293 cells via transient
transfection with either Hype-5 or Hype-293 (OZ Biosciences, San Diego, CA) at a 1:1.5 ratio (mg of DNA: mL of transfection reagent)
using 1 mg of plasmid per 1 million cells, similar to our previous reports (Kober et al., 2015). Media from supernatants were harvested
after 72-96 hours by centrifugation, concentrated to 1/10 of the original volume using a 10 kDa cutoff membrane (Ultracel Ultrafiltra-
tion Discs, EMD Millipore) and adjusted to pH 8.5 and 5 mM imidazole. The concentrated protein was purified using Ni-NTA
Superflow resin (QIAGEN, Hilden, Germany) and eluted in 5 mL of buffer containing 50 mM K2HPO4 (pH 8), 300 mM NaCl, and
250 mM imidazole. The eluted protein was concentrated and purified by size exclusion chromatography (Superdex75 Increase
10/300 GL for VWA in 20 mM Tris (pH 8) and 150 mM NaCl and Superdex 200 Increase 10/300 GL for CAT-CYS-VWA in 20 mM
HEPES and 150 mM NaCl (pH 7.4), GE Healthcare). Purified CLCA1 VWA was dialyzed into buffer containing 20 mM HEPES (pH
7.4) and 150 mM NaCl and concentrated in a 10,000 kDA cutoff centrifuge concentrator (Vivaspin 500, Sartorius) to 12 mg ml-1,
as calculated from absorbance at 280 nm, for crystallization. Protein purity was assessed by Coomassie staining of SDS-PAGE.
Crystallization, structure determination, and analysis
Crystals of CLCA1 VWA (302-476) were grown at 17C by hanging drop vapor diffusion by mixing 1:1 with well solution containing
0.2 M HEPES pH 7.5, 0.1 M CaCl2, 28% PEG 400 or by streak seeding into the same conditions containing 5% glycerol. Crystals
formed within 6 days. Crystals were flash frozen under a nitrogen stream at 160C. Data were collected at the Advanced Light
Source, beamline 4.2.2 (Berkeley, CA) and scaled and processed to 2.0 A˚ using XDS (Kabsch, 2010). A molecular replacement so-
lution was found with PHASER (TFZ = 10.2) using uncharacterized membrane spanning protein from Vibrio fischeri (4RCK) (poly-Ala
model) as the probe, locating twomolecules in the asymmetric unit (ASU) for a solvent content of 61%. The initial solution was refined
by rigid body refinement in PHENIX (Adams et al., 2010) and initially built using AUTOBUILD in PHENIX. The model was improved
by iterative rounds of manual rebuilding in COOT (Emsley et al., 2010) and refinement using PHENIX. Secondary structure restraints
were used during refinement and hydrogens were added as a riding model in the final rounds. Simulated annealing was used early
in refinement, and optimization of X-ray and ADP or stereochemistry weight was applied in later rounds. The final model is 94%
complete with 17 C-terminal residues (460-476) in both chains and the first N- terminal residue (302) in chain B not visible in the elec-
tron density. Chain A contained three N-terminal residues (ETG 299-301) that are a remnant of the vector-encoded signal sequence
(Aricescu et al., 2006). LigPlot+ (Laskowski and Swindells, 2011) was used to analyze cation contacts. Solvent accessibility calcu-
lations were carried out using NACCESS (Hubbard and Thornton, 1993). For structure-based alignment, amino acid sequences were
aligned using Clustal Omega (Sievers et al., 2011) and residue conservation scored by ESPript (Robert andGouet, 2014a). Secondary
structure predictions were generated in JPRED4 (Drozdetskiy et al., 2015). All crystallographic and analysis software used were
compiled and distributed by the SBGrid resource (Morin et al., 2013) and diffraction images were archived with the SB Data Grid
(Meyer et al., 2016). Crystals of CLCA1 VWA (302-478) were grown under similar conditions and diffracted to 2.6 A˚. The structure
was solved by isostructural replacement of CLCA1 VWA (302-476), and iteratively refined and rebuilt as above. The final model con-
sisted of residues 302-461 (chain A) and 303-459 (chain B).
Small angle X-ray scattering
SAXS data was obtained at the Advanced Light Source on the SIBYLS beamline 12.3.1 (Dyer et al., 2014). Thirty-three exposures of
0.3 s were obtained for each protein at 1-10 mg/mL and scattering from the dialysis buffer (20 mMHEPES pH 7.4, 150 mMNaCl, and
2% glycerol) was subtracted. Data were inspected for quality and scale-merged in scA˚tter 3.0g (Rambo, 2015). Data was subse-
quently analyzed in the ATSAS 2.8.4 suite (Franke et al., 2017) using PRIMUS (Konarev et al., 2003). Guinier analysis showed no ra-
diation damage, aggregation or concentration effects. I(0) and the pair distance distribution function P(r) were calculated in GNOM
(Svergun, 1992) within PRIMUS. Ten low-resolution ab initio models from DAMMIN (Franke and Svergun, 2009) were automatically
averaged using DAMAVER (Volkov and Svergun, 2003) and converted to a surface map using SITUS (Wriggers and Chacon, 2001).
Graphical Representation of Structures
All molecular graphics images were produced using PyMOL.
Heterologous expression of CLCA1 and Western Blotting
HEK293T cells were grown to 70%–90% confluency and transfected with CLCA1 VWA domain constructs and 293Fectin at a 1:2
ratio (mg of DNA: mL of transfection reagent) using 1 mg of plasmid DNA per 1 million cells. After 24 hours, supernatants were mixed
with 2x SDS containing 2-mercaptoethanol sample buffer. Cells were pelleted and lysed in PBS-1% Triton X-100, then diluted in
2x SDS containing 2-mercaptoethanol sample buffer and sonicated. Samples were boiled for 5 minutes, then loaded on a
4%–12% Bis-Tris NuPage gel (Life Technologies). Proteins were transferred to nitrocellulose membranes using an iBlot Gel transfer
device (Life Technologies). Membranes were blocked with 0.5% blotting-grade blocker nonfat milk (Bio-Rad) in PBS with 0.1%
Tween-20. HRP-conjugated anti-6-histidine antibody (Bethyl Laboratories) diluted 1:5000 in blocking buffer was incubated on the
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membrane for 10 minutes at room temperature. Following three washes with PBS-Tween-20, signal was detected using Pierce ECL
Western Blotting Substrate (Thermo Fisher Scientific, Rockford, IL). Developed films were scanned.
Circular Dichroism
CD spectroscopy measurements were performed using an Chirascan spectropolarimeter equipped with a Peltier temperature
controller (Applied Photophysics). A 1 cm path length cuvette was used and the protein concentration was 50 mg/mL. Thermal dena-
turation experiments were carried out in 20 mM Tris pH 8.0, 100 mM NaCl and 1 mM of either EDTA, MgCl2, or CaCl2. For reducing
conditions, the buffer contained 1mMDTT. Ellipticity wasmeasured at 222 nm in 1C steps from 20 to 90C at a rate of 1C/min. Data
was analyzed using ProScan software (Applied Photophysics).
Differential Scanning Fluorimetry
Thermal stability was assessed by differential scanning fluorimetry (DSF) on protein purified by size exclusion chromatography. The
Protein Thermal Shift kit (Applied Biosystems) was used according to manufacturer’s instructions. Briefly, protein was concentrated
to 0.5 mg/mL after buffer exchange into 20 mMHEPES pH 7.5, 150 mMNaCl and 1mM of either EDTA, MgCl2, CaCl2 or DTT. 5 mL of
reaction buffer and 2.5 mL 8x fluorescent dye were added to 12.5 mL protein on ice. Melt-curve experiments were performed using
Fast7500 qPCRmachine (Applied Biosystems) starting at 25C and with continuous 1% ramp to 95C (roughly at 1C/min). The data
were analyzed using Protein Thermal Shift software (Applied Biosystems).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses for differential scanning fluorimetry (DSF) experiments, specifically for melting temperature (TM) determination,
were performed using Protein Thermal Shift software (Applied Biosystems). Representative derivative-curve melting temperatures
from three (n = 3) independent experiments are shown. Melting temperature data are represented as mean ± SEM of triplicate
(n = 3) samples. For circular dichroism (CD) experiments, statistical analyses, specifically for TM determination, were performed using
the ProScan software (Applied Photophysics). Representative spectra of three (n = 3) independent experiments is shown. CD spectra
are plotted asmean ellipticity per residue ± SD of triplicate (n = 3) recordings. Melting temperature data are represented as the calcu-
lated melting temperature using a sigmoid curve fit and estimated error reported from the ProScan software. Statistical details are
also included in Figure 3 legends.
DATA AND CODE AVAILABILITY
Coordinates and structure factors for CLCA1 VWA (302-476) and CLCA1 VWA (302-478) have been deposited in the RCSB Protein
Data Bankwith accession numbers PBD: 6PYOand 6PYX, respectively. SAXS data for CLCA1 VWA (302-476) andCLCA1CAT-CYS-
VWA (22-477) have been deposited in the SASBDB with accession numbers SASBDB: SASDH24 and SASDH34, respectively.
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Related to Methods 
Table S1. Primer sequences used in study 
Primer 5’ – 3’ sequence 
hCLCA1 VWA (302-476) 
forward 
GAAACCGGTATTGGACAAAGAATTGTGTGT 
hCLCA1 VWA (302-476) reverse CGGGGTACCTGAAAGGGCCCCAAAAGCATC 
hCLCA1 VWA (302-478) 
forward 
GAAACCGGTATTGGACAAAGAATTGTGTGT 
hCLCA1 VWA (302-478) reverse CGGGGTACCTCCTGATGAAAGGGCCCCAAAAGC 
hCLCA1 CAT-CYS-VWA (22-
477) forward 
GAAACCGGTAATTCACTCATTCAGCTGAAC 
hCLCA1 CAT-CYS-VWA (22-
477) reverse 
CGGGGTACCTGAAAGGGCCCCAAAAGCATC 
hCLCA1 C308S forward GGTATTGGACAAAGAATTGTGAGTTTAGTCCTTGACAAATCTG 
hCLCA1 C308S reverse CAGATTTGTCAAGGACTAAACTCACAATTCTTTGTCCAATACC 
hCLCA1 C386S forward GGGACGTCCATCAGCAGCGGGCTTC 
hCLCA1 C386S reverse GAAGCCCGCTGCTGATGGACGTCCC 
hCLCA1 C421S forward GACAACACTATAAGTGGGAGCTTTAACGAGGTCAAAC 
hCLCA1 C421S reverse GTTTGACCTCGTTAAAGCTCCCACTTATAGTGTTGTC 
hCLCA1 E157Q forward AGGGCATTTGTCCATCAGTGGGCTCATCTA 
hCLCA1 E157Q reverse ACCTTGTGGTCCATATTCAGCTAACTTTTT 
 
 
 
  
  
Figure S1 (Related to Figure 1). Superposition of hCLCA1 VWA Domain Chains A and B 
within the Asymmetric Unit 
A) Alignment of hCLCA1 VWA domain chains A (cyan) and B (green) within the asymmetric 
unit, with a Cα RMSD of 0.3 Å. MIDAS residues, invariant disulfides and S357 are highlighted. 
Pseudoligand residue from chain A (E299) and chain B (D403) are also shown. The N-termini 
(N) and C-termini (C) of each chain are labeled. 
 
 
 
 
 
 
 
 
 
 Related to Table 1 
Table S2. Crystallographic statistics for human CLCA1 VWA 302-478 
Data collection statistics 
Space Group C2 
Unit Cell 	  	  	  	  	  a,	  b,	  c	  (Å)	   103.4,	  74.5,	  75.4	  	  	  	  	  	  α,	  β,	  γ	  (º)	   90,	  109.4,	  90	  
Source ALS 4.2.2 
Wavelength(Å) 1.0000 
Resolution(Å) 59.79 – 2.60 (2.72-2.60) 
Rmerge  0.266 (1.734) 
CC1/2 0.977 (0.328) 
Completeness(%) 99.6 (98.1) 
Redundancy 3.6 (3.3) 
I/σ(I) 4.6 (0.6) 
Refinement statistics 
Rwork (%) 21.82 
Rfree (%) 27.87 
Amino Acid Residues(#) 320 
Waters (#) 82 
RMSD bond length (Å)/angles(°) 0.008/0.906 
Wilson B (Å2) 
40.5 
Average B protein (Å2) 42.32 
Average B water (Å2) 40.62 
Average B Ca2+ (Å2) 40.12 
Ramachandran  
     %Favored 94.3 
     %Allowed 5.7 
     %Outliers 0 
Rotamer outliers (%) 0 
Clashscore  8.91 
Molprobity  1.86 
Luzzati Error 0.393 
PDB ID 6PYX 
 
 
 
  
Figure S2 (Related to Figure 1).  Superposition of crystal structures of CLCA1 VWA Domain 
302-476 and 302-478. The structures are extremely similar (Cα RMSD of 0.33 Å). A) Alignment 
of chain B from CLCA1 VWA domain constructs containing residues 302-476 (green) and 
residues 302-478 (orange). B) Alignment of chain A from hCLCA1 VWA domain constructs 
containing residues 302-476 (cyan) and residues 302-478 (yellow). MIDAS residues, invariant 
disulfides and S357 are highlighted. Pseudo-ligand residue from chain A (E299) and chain B 
(D403) are also shown. The N-termini (N) and C-termini (C) of each chain are labeled. 
 
 
 
 
 
 
  
Figure S3 (Related to Figure 2). Difference Electron Density for the MIDAS and Ca2+ Ion 
Difference electron density (2mFo-DFc contoured at 2σ) for the CLCA1 VWA MIDAS residues 
of chain B (green), including E299 from chain A (cyan) and calcium ion (grey).  
 
 
 
  
